Protagonist Therapeutics Inc Stock Research

Market Summary

USD21.76+1.03

Market Closed

4.97%

PTGX Stock Price

PTGX RSI Chart

PTGX Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-8.15

Price/Sales (Trailing)

39.05

EV/EBITDA

-2.16

Price/Free Cashflow

-9.53

PTGX Price/Sales (Trailing)

PTGX Profitability

EBT Margin

-267.76%

Return on Equity

-53.41%

Return on Assets

-46.11%

Free Cashflow Yield

-10.49%

PTGX Fundamentals

PTGX Revenue

Revenue (TTM)

26.6M

Revenue Y/Y

-100%

Revenue Q/Q

-100%

PTGX Earnings

Earnings (TTM)

-127.4M

Earnings Y/Y

7.35%

Earnings Q/Q

-9.48%

Price Action

52 Week Range

6.9126.00

(Low)(High)

Last 7 days

-4.5%

Last 30 days

29.0%

Last 90 days

115.5%

Trailing 12 Months

-12.8%

PTGX Financial Health

Current Ratio

7.53

PTGX Investor Care

Shares Dilution (1Y)

3.14%

Diluted EPS (TTM)

-2.6

Peers (Alternatives to Protagonist Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	292.5B	1.4B	4.26%	16.70%	-145.95	206.55	20.37%	-37.45%
ABBV	279.0B	58.1B	3.16%	0.41%	23.57	4.81	3.30%	2.55%
REGN	87.7B	12.2B	8.38%	20.64%	20.22	7.2	-24.26%	-46.28%
VRTX	76.6B	8.9B	7.34%	21.47%	23.05	8.57	17.91%	41.84%
ALNY	23.6B	1.0B	0.38%	16.30%	-20.87	22.76	22.88%	-32.64%
SRPT	11.4B	933.0M	6.57%	69.72%	-16.14	12.17	32.93%	-67.99%
UTHR	9.8B	1.9B	-12.71%	24.69%	13.48	5.06	14.88%	52.86%
MID-CAP
MDGL	4.2B	504.0K	-13.71%	151.72%	-14.16	2.5K	-66.53%	-22.12%
RARE	2.6B	363.3M	-14.67%	-45.80%	-3.7	7.2	3.39%	-55.81%
BPMC	2.6B	204.0M	14.09%	-32.77%	-4.68	12.79	13.30%	13.44%
MRTX	2.3B	12.4M	-16.66%	-53.11%	-3.09	183.95	-	-27.34%
SMALL-CAP
CPRX	1.7B	214.2M	7.73%	105.76%	20.83	8.08	52.10%	110.42%
MGNX	414.0M	151.9M	9.40%	-22.95%	-3.46	2.72	96.19%	40.75%
CRBP	28.4M	-	143.57%	1148.86%	-0.67	19.11	-77.61%	7.22%
CYTK	3.2M	94.6M	-19.34%	-5.32%	-0.01	0.03	34.30%	-80.65%

Financials for Protagonist Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-20.3%	26,581,000	33,350,667	40,120,333	46,890,000	27,357,000
Operating Expenses	-5.5%	157,954,000	167,071,000	178,980,000	169,825,000	153,202,000
S&GA Expenses	-1.9%	31,739,000	32,367,000	32,722,000	31,746,000	27,196,000
R&D Expenses	-6.3%	126,215,000	134,704,000	146,258,000	138,079,000	126,006,000
EBITDA	0.1%	-124,595,000	-124,669,000	-	-	-
EBITDA Margin	0.1%	-2.66	-2.66	-	-	-
Earnings Before Taxes	-	-125,551,000	-	-	-	-
EBT Margin	0%	-2.68	-2.68	-	-	-
Net Income	2.1%	-127,393,000	-130,106,000	-132,678,000	-122,483,000	-125,551,000
Net Income Margin	-8.3%	-2.83	-2.61	-	-	-
Free Cahsflow	3.1%	-104,362,000	-107,734,000	-118,009,000	-108,966,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-12.1%	248	282	311	348	348
Current Assets	-12.1%	243	277	304	342	341
Cash Equivalents	-17.6%	126	153	120	98.00	124
Net PPE	-12.2%	2.00	2.00	2.00	2.00	2.00
Liabilities	-16.2%	32.00	39.00	43.00	47.00	48.00
Current Liabilities	-15.2%	31.00	37.00	40.00	43.00	44.00
Shareholder's Equity	-11.5%	216	244	268	302	300
Retained Earnings	-6.8%	-536	-502	-471	-430	-409
Additional Paid-In Capital	0.8%	753	747	740	733	710
Accumulated Depreciation	4.9%	5.00	5.00	5.00	4.00	-
Shares Outstanding	0.3%	49.00	49.00	49.00	49.00	48.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-4.5%	-108	-103	-106	-116	-107
Share Based Compensation	2.1%	24.00	24.00	23.00	20.00	16.00
Cashflow From Investing	-20.7%	91.00	115	13.00	-13.54	-15.86
Cashflow From Financing	-7.9%	19.00	20.00	21.00	146	130

Risks for PTGX

What is the probability of a big loss on PTGX?

89.6%

Probability that Protagonist Therapeutics stock will be more than 20% underwater in next one year

89.2%

Probability that Protagonist Therapeutics stock will be more than 30% underwater in next one year.

68.8%

Probability that Protagonist Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PTGX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Protagonist Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for PTGX

Cumulative Returns on PTGX

20.8%

5-Year Cumulative Returns

50.2%

3-Year Cumulative Returns

What are the long-term rolling returns for PTGX?

FIve years rolling returns for Protagonist Therapeutics.

Annualized Returns

Which funds bought or sold PTGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	MetLife Investment Management, LLC	unchanged	-	59,307	260,902	-%
2023-02-28	Voya Investment Management LLC	reduced	-4.82	285,842	1,520,840	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-	-3,000	-	-%
2023-02-15	Metropolitan Life Insurance Co/NY	unchanged	-	6,868	31,868	-%
2023-02-15	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	reduced	-18.5	9,000	164,000	-%
2023-02-15	LAZARD ASSET MANAGEMENT LLC	unchanged	-	16,000	69,000	-%
2023-02-15	Bridgefront Capital, LLC	sold off	-100	-102,000	-	-%
2023-02-15	JANE STREET GROUP, LLC	added	443	522,770	609,770	-%
2023-02-15	ALLIANCEBERNSTEIN L.P.	added	35.5	254,322	591,322	-%
2023-02-15	Financial Gravity Asset Management, Inc.	new	-	197	197	-%

Latest Funds Activity

Are funds buying PTGX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own PTGX

No. of Funds

Protagonist Therapeutics News

Schedule 13G FIlings of Protagonist Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 20, 2023	biotechnology value fund l p	5.1%	2,630,650	SC 13G
Feb 14, 2023	biotechnology value fund l p	1.2%	577,541	SC 13G/A
Feb 14, 2023	rtw investments, lp	7.3%	3,591,986	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	0.6%	316,500	SC 13G/A
Feb 09, 2023	farallon capital partners, l.p.	1.2%	601,195	SC 13G/A
Feb 09, 2023	vanguard group inc	6.30%	3,097,714	SC 13G
Jan 31, 2023	blackrock inc.	7.4%	3,652,157	SC 13G/A
Jan 11, 2023	johnson & johnson	4.98%	0	SC 13G/A
Jan 10, 2023	state street corp	7.71%	3,792,926	SC 13G/A
Jan 03, 2023	citadel advisors llc	3.6%	6	SC 13G

PTGX Fair Value

Protagonist Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Protagonist Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	1.29 -94.07%	1.40 -93.57%	1.68 -92.28%	2.31 -89.38%	3.14 -85.57%
Current Inflation	1.28 -94.12%	1.39 -93.61%	1.63 -92.51%	2.18 -89.98%	2.90 -86.67%
Very High Inflation	1.28 -94.12%	1.37 -93.70%	1.58 -92.74%	2.03 -90.67%	2.62 -87.96%

Historical Protagonist Therapeutics Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Protagonist Therapeutics

View All Filings

Date Filed	Form Type	Document
Mar 20, 2023	SC 13G	Major Ownership Report
Mar 15, 2023	10-K	Annual Report
Mar 15, 2023	8-K	Current Report
Mar 15, 2023	S-8	Employee Benefits Plan
Mar 10, 2023	8-K	Current Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	SC 13G	Major Ownership Report
Feb 09, 2023	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for PTGX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-16	Ali Asif	acquired	-	-	10,625	chief financial officer
2023-01-16	MOLINA ARTURO MD	acquired	-	-	3,125	chief medical officer
2023-01-16	Gupta Suneel	acquired	-	-	20,625	chief development officer
2022-12-28	PATEL DINESH V PH D	gifted	-	-	-3,116	president and ceo
2022-11-16	Liu David Y	acquired	231,802	2.30697	100,479	chief r&d strategy officer
2022-11-15	MOLINA ARTURO MD	acquired	-	-	21,250	chief medical officer
2022-08-23	PATEL DINESH V PH D	acquired	84,200	4.21	20,000	president and ceo
2022-05-04	PATEL DINESH V PH D	gifted	-	-	-3,000	president and ceo
2022-05-04	PATEL DINESH V PH D	acquired	66,273	4.21	15,742	president and ceo
2022-05-03	Waddill William D.	acquired	103,080	8.59	12,000	-

About Protagonist Therapeutics

Dinesh V. Patel

www.protagonist-inc.com

120

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Operations
License and collaboration revenue - related party	$ 26,581,000	$ 27,357,000	$ 28,628,000
Revenue from Contract with Customer, Product and Service [Extensible List]	License and Collaboration Agreement..	License and Collaboration Agreement..	License and Collaboration Agreement..
Operating expenses:
Research and development	$ 126,215,000	$ 126,006,000	$ 74,506,000
General and administrative	31,739,000	27,196,000	18,638,000
Total operating expenses	157,954,000	153,202,000	93,144,000
Loss from operations	(131,373,000)	(125,845,000)	(64,516,000)
Interest income	4,060,000	443,000	900,000
Interest expense			(598,000)
Loss on early repayment of debt			(585,000)
Other expense, net	(80,000)	(149,000)	(46,000)
Loss before income tax expense	(127,393,000)	(125,551,000)	(64,845,000)
Income tax expense	0	0	(1,305,000)
Net loss	$ (127,393,000)	$ (125,551,000)	$ (66,150,000)
Net loss per share, basic	$ (2.60)	$ (2.71)	$ (1.92)
Net loss per share, diluted	$ (2.60)	$ (2.71)	$ (1.92)
Weighted-average shares used to compute net loss per share, basic	49,042,232	46,322,910	34,396,446
Weighted-average shares used to compute net loss per share, diluted	49,042,232	46,322,910	34,396,446

PTGX Balance Sheet

2022-12-31

Consolidated Balance Sheets $ in Thousands, $ in Millions	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Current assets:
Cash and cash equivalents	$ 125,744	$ 123,665
Marketable securities	111,611	203,235
Receivable from collaboration partner - related party	10	1,566
Research and development tax incentive receivable		2,792
Prepaid expenses and other current assets	5,712	9,478
Total current assets	243,077	340,736
Property and equipment, net	1,565	1,798
Restricted cash - noncurrent	225	225
Operating lease right-of-use asset	3,061	4,936
Total assets	247,928	347,695
Current liabilities:
Accounts payable	3,640	1,600
Payable to collaboration partner - related party	69	899
Accrued expenses and other payables	24,955	37,716
Deferred revenue - related party		1,601
Operating lease liability - current	2,515	2,200
Total current liabilities	31,179	44,016
Operating lease liability - noncurrent	1,141	3,658
Total liabilities	32,320	47,674
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.00001 par value, 90,000,000 shares authorized; 49,339,252 and 47,838,330 shares issued and outstanding as of December 31, 2022 and 2021, respectively
Additional paid-in capital	752,722	709,682
Accumulated other comprehensive loss	(359)	(299)
Accumulated deficit	(536,755)	(409,362)
Total stockholders' equity	215,608	300,021
Total liabilities and stockholders' equity	$ 247,928	$ 347,695